Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) is integrating Weave Bio’s artificial intelligence platform into preparations for a planned buntanetap New Drug Application, aiming to shorten the time between …
Annovis Uses AI Platform to Accelerate Buntanetap FDA Filing Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) expects top-line data and regulatory submissions in 2027 from its fully enrolled pivotal Phase 3 Alzheimer’s disease trial, putting its lead drug …
Annovis Sets 2027 Alzheimer’s Readout as Phase 3 Fills Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) more than doubled second-quarter research spending as its pivotal Phase 3 Alzheimer’s disease trial reached full enrollment at 850 patients, positioning the …
Annovis R&D Costs Surge as Alzheimer’s Trial Reaches Full Enrollment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has completed enrollment in its pivotal Phase 3 Alzheimer’s disease trial, positioning the biotechnology company for two planned U.S. regulatory submissions beginning …
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial Read More MALVERN, PA — Annovis Bio (NYSE: ANVS) has promoted Cheng Fang to chief scientific officer as the biotechnology company prepares for pivotal clinical and regulatory milestones for its lead drug …
Annovis Promotes Research Chief as Lead Drug Nears Key Trial Read More MALVERN, PA — Annovis Bio (NYSE: ANVS) has regained compliance with New York Stock Exchange listing standards a year after falling below required market capitalization and stockholders’ equity thresholds, removing …
Annovis Regains NYSE Compliance Ahead of Listing Deadline Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently published results from a Phase 2/3 clinical trial evaluating its investigational drug buntanetap in patients with mild to moderate Alzheimer’s disease, …
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received a U.S. patent covering the use of its drug candidate buntanetap to prevent and treat neurological injuries linked to brain …
Annovis Secures U.S. Patent for Buntanetap Neurological Use Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More